Sydbank: Expanded ALK approval is good news
It is good news that the FDA has approved ALK's ragweed allergy tablet for use in children – though it won't cause a huge increase in short term sales, says Sydbank senior analyst Søren Løntoft Hansen.
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
From now on, ALK-Abelló will also be able to market its allergy tablet, Ragwitek, as suitable for children aged 5 and above in the US. Although this is of course good news, it isn't something that will generate a lot of sales in the short term, says senior analyst at Sydbank, Søren Løntoft Hansen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK gains important approval on difficult US market
For subscribers
ALK has decent growth forecast in sight
For subscribers
